EGCG may indirectly influence GLP-1 pathways or exert synergistic effects with other compounds to improve glucose metabolism and promote fat oxidation, contributing to overall metabolic well-being
In Phase 2 trial settings, participants have shown gradual but meaningful reductions in body weight over several months, alongside improvements in blood glucose control, blood pressure, and metabolic markers
Always consult with your healthcare provider before starting, stopping, or changing any medication
J., Fernndez Land, L., Mao, H., Cui, X., Karanikas, C
North America dominated the GLP-1 analogues market with the largest market share of 40% in 2025
The protocols vary, none are clinically supervised, and the outcomes reported by users include both the weight loss seen in trials and the side effects